Neonatal screening for cystic fibrosis: France rises to the challenge

Journal of Inherited Metabolic Disease

Volumn 26, Issue 8, 2003, Pages 729-744

  Farriaux, J P ^a   Vidailhet, M ^a   Briard, M L ^a   Belot, V ^a   Dhondt, Jean Louis ^a,b  

^a AFDPHE   (France)

^b Centre Hospitalier Saint Philibert GHICL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; TRANSMEMBRANE CONDUCTANCE REGULATOR; TRYPSIN;

ANXIETY; ARTICLE; BLOOD SAMPLING; CLINICAL PROTOCOL; COMPETENCE; CYSTIC FIBROSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DNA DETERMINATION; FRANCE; GENE MUTATION; GENETIC HETEROGENEITY; GEOGRAPHY; HEALTH PROGRAM; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; INFORMED CONSENT; LEGAL ASPECT; MEDICAL ETHICS; MUTATIONAL ANALYSIS; NEWBORN; NEWBORN SCREENING; NUCLEOTIDE SEQUENCE; PATIENT CARE; PATIENT REFERRAL; SOCIAL SECURITY; STAFF TRAINING;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FRANCE; HUMANS; INFANT, NEWBORN; MUTATION; NEONATAL SCREENING; PARENTS; TRYPSIN;

EID: 0942266377     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BOLI.0000009921.42503.c2     Document Type: Article

References (14)

1. Al-Jader LN, Goodchild MC, Ryley HC, Harper PS (1990) Attitudes of parents of cystic fibrosis children towards neonatal screening and antenatal diagnosis. Clin Genet 38: 460-465.
2. Corbetta C, Seia M, Bassotti A, Ambrosioni A, Giunta A, Padoan R (2002) Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population. J Med Screen 9: 60-63.
3. Dhondt JL, Farriaux JP (1997) Impact of French legislation on neonatal screening. In Knoppers BM, ed. Human DNA: Law and Policy. The Hague: Kluwer Law International, 285-289.
4. Dhondt JL, Farriaux JP, Briard ML, Boschetti R, Frézal J (1993a) Results of pilot screening activities in the French neonatal screening program - cystic fibrosis, congenital adrenal hyperplasia and sickle cell disease. Screening 2: 87-89.
5. Dhondt JL, Farriaux JP, Briard ML, Boschetti R, Frézal J (1993b) Neonatal screening in France. Screening 2: 77-85.
6. Duchassaing D, Dingeon B, Chalas J, Coude M, Coulhon M-P, Launay J-M (2002) Génétique moléculaire: les 'bonnes pratiques' pré- et postanalytiques. Ann Biol Clin 60: 617-621.
7. Feldmann D, Guittard C, Des Georges M, et al (2001) Diagnostic moléculaire de la mucoviscidose: évaluation de la trousse Elucigene® CF20 dans le sang et les cellules buccales. Ann Biol Clin 59: 277-283.
8. Ferec C, Verlingue C, Parent P, et al (1995) Neonatal screening for cystic fibrosis: result of a pilot study using both immunoreactive trypsinogen and cystic fibrosis gene mutation analyses. Hum Genet 96: 542-548.
9. Newton CR, Graham A, Heptinstall IE, et al (1989) Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 17: 2503-2516.
10. Pollitt RJ, Green A, McCabe CJ, et al (1997) Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technology Assessment 1(7) (http://www.ncchta.org).
11. Ranieri E, Ryall RG, Morris CP, et al (1991) Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis. Br Med J 302: 1237-1240.
12. Tluczek A, Mischler EH, Farrell PM, et al (1992) Parents' knowledge of neonatal screening and response to false-positive cystic fibrosis testing. J Dev Behav Pediatr 13: 181-186.
13. Wilcken B, Chalmers GR (1985) Reduced morbidity in patients with cystic fibrosis detected by neonatal screening. Lancet 2: 1319-1321.
14. Wilson JMG, Jungner G (1968) Principles of Screening for Disease. Geneva: World Health Organization, 26-39.